Previous 10 | Next 10 |
Illinois is ringing in the new decade by becoming the 11th state in the country and the District of Columbia to allow the legal sale and purchase of marijuana. More news on: Aurora Cannabis Inc., Cronos Group Inc., Tilray, Inc., News on the U.S. economy, News on ETFs, Read more ...
In an animal model of the disease, GB Sciences' formulations were able to reduce Parkinson's disease-like behavioral symptoms 'back to baseline' with negligible side effects. LAS VEGAS , Dec. 20, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical re...
LAS VEGAS , Dec. 5, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production operation. This transaction will signif...
The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana. LAS VEGAS , Nov. 18, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) completed the sale on November 15, 2019 ...
LAS VEGAS , Nov. 6, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces a delay in the sale of GB Sciences Louisiana LLC. On September 16, 2019, GB Sciences, Inc. (the "Company"), filed a Current Report on Form 8-K disclosing that the Company had signed ...
LAS VEGAS , Oct. 31, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that on October 23 rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector with deep expertise in patents a...
GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine Canada NewsWire LAS VEGAS, Oct. 9, 2019 In the October 2019 Issue of Marijuana Business Magazine, Dr. Andrea Small-Howard Explains Why GBS is Well Positioned in New Market Segments...
GB Sciences (OTCQB: GBLX) today announced that it has filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. for $16 million. The stake will be bought by Wellcana Plus at a fee of $7 million in cash at closing, $1 million in cash within 60 days of closing, an...
GB Sciences (OTCQB: GBLX) today announced that it has filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. for $16 million. The stake will be bought by Wellcana Plus at a fee of $7 million in cash at closing, $1 million in cash within 60 days of closing, an...
LAS VEGAS , Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019 , filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus LLC, affiliated through its mana...
News, Short Squeeze, Breakout and More Instantly...
LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infect...
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which...
LAS VEGAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selec...